Genome-wide association study

OliX Pharmaceuticals Commences Patient Dosing in Phase 1 Clinical Trial of OLX75016 for MASH

Retrieved on: 
Tuesday, February 13, 2024
Health, Genetics, Fitness & Nutrition, Clinical Trials, Pharmaceutical, Biotechnology, Therapy, KOSDAQ, Genome-wide association study, Inflammation, Obesity, Hope, GWAS, Safety, MASH, Patient, Gene, Clinical trial, Cirrhosis, NASH, RNA interference, Non-alcoholic fatty liver disease

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the first participant was dosed today with OLX75016.

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the first participant was dosed today with OLX75016.
  • OLX75016 is being developed to provide a novel treatment approach for metabolic dysfunctions associated with non-alcoholic fatty liver disease linked to obesity.
  • The phase 1 trial is ongoing in Brisbane, Australia.
  • This is how we believe OLX75016 is set apart, and we anticipate this novel therapeutic to bring hope to patients with multiple metabolic diseases, starting in phase 1 clinical trial."

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Retrieved on: 
Wednesday, January 31, 2024
Health, Genetics, Health Technology, Research, Science, Biotechnology, Genomics, Oxford Nanopore Technologies, Growth, DNA, Gene, 3D, University, Database, Weill Cornell Medicine, CSO, Genome-wide association study, Master of Science, Wellcome Sanger Institute, GWAS, Algorithm, Molecular biology, Doctor of Philosophy, Antibiotics

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).
  • Dan’s deep expertise in genomics technology development and commercialisation will be key to achieving the next phase of Enhanc3D Genomics’ growth.
  • Dr Hazel Jones, Chief Operating Officer and interim Chief Executive Officer, Enhanc3D Genomics, said: “Dan joins us at an exciting stage in the Company’s development as we begin to steer towards commercialisation.
  • I look forward to working alongside Dan as he joins the team.”
    Dr Dan Turner, Chief Scientific Officer, Enhanc3D Genomics, commented: “Enhanc3D Genomics has an exceptional reputation in the field of 3D genomics, and I’m delighted to take this opportunity to help drive the development of its technology further.

deCODE genetics: A sequence variant that increases risk of pregnancy loss

Retrieved on: 
Monday, January 29, 2024
Woman, Synaptonemal complex, Genetic distance, Biology, Genome-wide association study, Genetics, Meiosis, Risk, Pregnancy, Chromosome, Genome, AMGN

Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.

Key Points: 
  • Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
  • A low-frequency missense variant in the SYCE2 gene was found to increase the risk of pregnancy loss by 22%.
  • The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
  • The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.

deCODE genetics: A sequence variant that increases risk of pregnancy loss

Retrieved on: 
Monday, January 29, 2024
Woman, Synaptonemal complex, Genetic distance, Biology, Genome-wide association study, Genetics, Meiosis, Risk, Pregnancy, Chromosome, Genome, AMGN

Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.

Key Points: 
  • Over 114 thousand women from Iceland, Denmark, the UK, USA, and Finland who have experienced pregnancy loss participated in a genome-wide association study, testing 50 million sequence variants.
  • A low-frequency missense variant in the SYCE2 gene was found to increase the risk of pregnancy loss by 22%.
  • The association with pregnancy loss does not account for embryos lost in early gestation before pregnancy has been detected so the effect of the variant on pregnancy success may be underestimated.
  • The findings reported in this study demonstrate that a variant with a substantial effect on recombinations can be maintained in the population despite increasing the risk of pregnancy loss.

Genetic Testing's Role in Personalized Medicine and Targeted Therapies for Respiratory Conditions - ResearchAndMarkets.com

Retrieved on: 
Monday, December 18, 2023
Health, Genetics, Personalized medicine, COPD, Genome-wide association study, Disorder, Prevalence, Granulomatous–lymphocytic interstitial lung disease, Privacy, Risk, Diagnosis, GWAS, Respiratory disease, Marker beacon, Region, Genetic testing, Health information management, Growth, Chronic obstructive pulmonary disease, Asthma, Cystic fibrosis, Agriculture, Pharmaceutical industry, Vaccine, Medical device

Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.

Key Points: 
  • Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions.
  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.
  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.

Enhanc3D Genomics Expands Leadership Team With the Appointment of Hazel Jones as Chief Operating Officer

Retrieved on: 
Monday, November 6, 2023
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, 3D, Combination, Genomics, AstraZeneca, Integrated business planning, Bachelor of Science, Doctor of Philosophy, Database, GWAS, University, Cancer research, Gene, Genome-wide association study, Algorithm, Clinical data management, Patient, Diagnosis, DNA, Nursing, Antibiotics, Biochemistry, Pharmacology

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer.
  • Hazel has over 10 years of senior leadership experience in oncology research.
  • Prior to joining Enhanc3D Genomics, Hazel held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D.
  • I am delighted to welcome Hazel to the team.”
    Dr Hazel Jones, Chief Operating Officer, Enhanc3D Genomics, added: “I’m delighted to join the team at such an exciting stage of the Company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”
    For more information about Enhanc3D Genomics, please visit: www.enhanc3dgenomics.com

OliX Pharmaceuticals Presents Preclinical Data Showing Synergistic Weight Loss from anti-NASH siRNA and Semaglutide Combination Treatment

Retrieved on: 
Thursday, May 11, 2023
Health, Genetics, Fitness & Nutrition, Clinical Trials, Pharmaceutical, Biotechnology, Obesity, Therapy, NASH, Weight loss, Research, GWAS, Metabolism, Fibrosis, KOSDAQ, DSM-IV codes, Genome-wide association study, Fatty liver disease, RNA interference, Cirrhosis, Dietary supplement

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company presented its latest study data from preclinical studies identifying synergistic effects in weight loss when using its non-alcoholic steatohepatitis (NASH) treatment candidate OLX702A in combination with semaglutide.

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company presented its latest study data from preclinical studies identifying synergistic effects in weight loss when using its non-alcoholic steatohepatitis (NASH) treatment candidate OLX702A in combination with semaglutide.
  • During the conference’s poster session, OliX revealed preclinical study results of OLX702A, addressing key mechanisms involved in NASH and obesity.
  • The combination data demonstrated an additional 10% reduction in weight compared to administering semaglutide alone.
  • Metabolic analysis suggests that the weight loss caused by OLX702A treatment is due to the increase in energy expenditure, which is distinct from incretin-based anti-obesity drugs like semaglutide.

deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease

Retrieved on: 
Monday, October 24, 2022
Sequence, Proteomics, Plasma, Disease, BMI, GPAM, NAFLD, Magnetic resonance imaging, NAFL, Patient, Hepatocellular carcinoma, Fatty liver disease, HIV disease progression rates, HCC, Risk, NASH, Cirrhosis, Liver, Genome-wide association study, Protein, Genetics, Genetic distance, Icelandic, Biomarker, Nature Genetics, Dietary supplement, Medical device, Medical imaging, Amgen

REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.

Key Points: 
  • Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets fornonalcoholic fatty liver disease (NAFLD).
  • REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.
  • Nonalcoholic fatty liver (NAFL), when over 5% of the liver is fat with no identifiable causes such as excessive alcohol consumption, is the first stage of NAFLD.
  • NAFL can progress to non-alcoholic steato-hepatitis (NASH) which can progress further into liver cirrhosis and hepatocellular carcinoma (HCC).

deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease

Retrieved on: 
Monday, October 24, 2022
Sequence, Proteomics, Plasma, Disease, BMI, GPAM, NAFLD, Magnetic resonance imaging, NAFL, Patient, Hepatocellular carcinoma, Fatty liver disease, HIV disease progression rates, HCC, Risk, NASH, Cirrhosis, Liver, Genome-wide association study, Protein, Genetics, Genetic distance, Icelandic, Biomarker, Nature Genetics, Dietary supplement, Medical device, Medical imaging, Amgen

REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.

Key Points: 
  • Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets fornonalcoholic fatty liver disease (NAFLD).
  • REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.
  • Nonalcoholic fatty liver (NAFL), when over 5% of the liver is fat with no identifiable causes such as excessive alcohol consumption, is the first stage of NAFLD.
  • NAFL can progress to non-alcoholic steato-hepatitis (NASH) which can progress further into liver cirrhosis and hepatocellular carcinoma (HCC).

The Michael J. Fox Foundation Remembers Visionary Philanthropist Mrs. Lily Safra

Retrieved on: 
Friday, July 22, 2022
Goal, Brain, Diagnosis, View, Education, The Michael J. Fox Foundation, Awareness, For Hope, Industry, Instagram, Twitter, Foundation, CEO, Culture, Parkinson's disease, Research, Genetics, Government, Partnership, Religion, Neurology, Board, Movement disorders, Multimedia, Volunteering, LEAPS, Organization, Leadership, Quality of life, Clinical trial, Fox Trial Finder, Genome-wide association study, Grief, Disease, Hope, Board of directors, Science, Memory, LinkedIn, Patient, NEW, Edmond, Program, Growth, MJFF, Lists of diseases, Medicine, Management, Pharmaceutical industry, PD, Facebook

Fox Foundation Board member Lily Safra, chairwoman of the Edmond J. Safra Foundation, passed away on July 9, 2022, at age 87

Key Points: 
  • Fox Foundation Board member Lily Safra, chairwoman of the Edmond J. Safra Foundation, passed away on July 9, 2022, at age 87
    Mrs. Safra's transformative generosity and leadership supported a wide range of The Michael J.
  • Fox Foundation for Parkinson's Research (MJFF) mourns the loss of visionary philanthropist and Foundation Board member Lily Safra , who passed away on Saturday, July 9, 2022 in Geneva, Switzerland.
  • As chairwoman of the Edmond J. Safra Foundation, Mrs. Safra provided transformative support to hundreds of organizations around the world in the name of her late husband, Edmond J. Safra.
  • Edmond J. Safra lived with Parkinson's disease (PD), and Mrs. Safra was deeply committed to finding a cure.